Upcoming event

Tags

Show all

Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?

European Urology, September 2021

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Lancet Oncol. , May 2021

The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer

European Urology, February 2021

Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab

European Urology, March 2021

Radical cystectomy against intravesical BCG for high-risk high-grade non-muscle invasive bladder cancer: Results from the randomized controlled BRAVO-feasibility study

Journal of Clinical Oncology, January 2021

Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer

BJU International, January 2021

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

The Lancet Oncology, November 2020

Treatment of high-grade non–muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial “NIMBUS”

European Urology, November 2020

An international collaborative consensus statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round delphi survey, and a consensus meeting

European Urology, October 2020

Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: Chemotherapy toxicity and pathological responses

European Urology, August 2020